Alkylator-based therapy in Waldenström’s macroglobulinemia (reviewed in Merlini and Treon21 ).
| Study . | N . | Setting . | Regimen . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|---|
| a ≥ 50% reduction in serum IgM levels. | |||||
| Abbreviations: CR, complete response; NA, not applicable; PR, partial response. Rx, previously treated; UnRx, previously untreated; Chl, chlorambucil; P, prednisone; M, melphalan; C, cyclophosphamide; V, Vincristine. | |||||
| Facon | 110 | UnRx | Chl (continuous) | 31% | NA |
| Kyle | 24 | UnRx | Chl (continuous) | 75% | 26 months |
| 22 | UnRx | Chl (intermittent) | 64% | 46 months | |
| Dimopoulos | 77 | UnRx | Chl, P | 72% | NA |
| Petrucci | 31 | UnRx | M,C,P → CP (continuous) | 74% | 66 months |
| Case | 33 | UnRx and Rx | M-2 (BCNU,V,M,P) | 82% | 43 months (CR), 39 months (PR) |
| Study . | N . | Setting . | Regimen . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|---|
| a ≥ 50% reduction in serum IgM levels. | |||||
| Abbreviations: CR, complete response; NA, not applicable; PR, partial response. Rx, previously treated; UnRx, previously untreated; Chl, chlorambucil; P, prednisone; M, melphalan; C, cyclophosphamide; V, Vincristine. | |||||
| Facon | 110 | UnRx | Chl (continuous) | 31% | NA |
| Kyle | 24 | UnRx | Chl (continuous) | 75% | 26 months |
| 22 | UnRx | Chl (intermittent) | 64% | 46 months | |
| Dimopoulos | 77 | UnRx | Chl, P | 72% | NA |
| Petrucci | 31 | UnRx | M,C,P → CP (continuous) | 74% | 66 months |
| Case | 33 | UnRx and Rx | M-2 (BCNU,V,M,P) | 82% | 43 months (CR), 39 months (PR) |